A Director at BioMarin Pharmaceutical Inc. is Exercising Options

Yesterday it was reported that a Director at BioMarin Pharmaceutical Inc. (BMRN), Elaine Heron, exercised options to buy 1,553 BMRN shares at $63.10 a share, for a total transaction value of $97.99K.

Following this transaction Elaine Heron’s holding in the company was increased by 3.37% to a total of $3.67 million.

See today’s analyst top recommended stocks >>

Based on BioMarin Pharmaceutical Inc.’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $383 million and GAAP net loss of $37.44 million. In comparison, last year the company earned revenue of $377 million and had a GAAP net loss of $16.79 million. Currently, BioMarin Pharmaceutical Inc. has an average volume of 792.1K.

Based on 14 analyst ratings, the analyst consensus is Strong Buy with an average price target of $128.70, reflecting a 67.4% upside. 13 different firms, including Cantor Fitzgerald and Citigroup, currently also have a Buy rating on the stock.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim.